Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Using Microbiome to Predict Durvalumab Toxicity in Post-CCRT NSCLC Patients (Microdurva)

NCT04680377 is registered in ClinicalTrials.gov with Jun Zhang, MD, PhD as lead sponsor.

NCT NCT04680377
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04680377 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Using Microbiome to Predict Durvalumab Toxicity in Post-CCRT NSCLC Patients (Microdurva)
Lead sponsor
Jun Zhang, MD, PhD
Phase
Observational
Overall status
Recruiting
Start date
April 12, 2021
Completion date
December 31, 2026
Enrollment
44 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced lung carcinoma, nsclc, stage iii